AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy

Pays $200m Upfront

The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.

Galbraith Susan
Susan Galbraith • Source: AstraZeneca

AstraZeneca PLC has kept a low profile in the oncology cell therapy space but efforts to catch up on its big pharma peers have been brewing since 2019 and have culminated in the acquisition of Neogene Therapeutics, Inc..

So said head of oncology R&D Susan Galbraith, who was speaking to Scrip shortly after the UK major announced it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business